We will be at the TD Cowen Health Care Conference in Boston, where our team will meet with industry leaders to discuss our efforts to improve the lives of patients with cardiovascular disease. Learn more about our science at?www.brbio.com. #cardioimmunology #cardiology #cardiovascularhealth
关于我们
Harnessing the power of immunotherapy to develop and deliver transformative medicines for patients with cardiovascular disease
- 网站
-
www.bitterrootbio.com
Bitterroot Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Palo Alto,California
- 类型
- 私人持股
- 创立
- 2021
地点
-
主要
3160 Porter Dr
US,California,Palo Alto,94304
Bitterroot Bio员工
-
Georgette Verdin
Chief People Officer - Passionate about leveraging culture and talent to realize business results
-
Sharline C.
-
Will Krause
Vice President Finance & Corporate Development
-
Cheralyn (Cher) McClurg Crokaerts
Executive Assistant/Executive Operations Manager| Operations, Executive Support
动态
-
We're #hiring a new Director/Senior Director, Clinical Operations in Boston, Massachusetts. Apply today or share this post with your network.
-
So much fun joining some of our fantastic Bitterroot Bio clinical team on our night out at the Boston Bruins vs Winnipeg Jets game last week! ?? While the scoreboard didn’t swing Boston’s way, the night was a win in every other sense. Swapan Chowdhury Sharon Crugnale Emily Dale Andrew Morrison Igor Quinones-Garcia
-
-
We're #hiring a new Manager / Sr Manager, Accounting Operations in Palo Alto, California. Apply today or share this post with your network.
-
We're #hiring a new Associate Director, Legal in Palo Alto, California. Apply today or share this post with your network.
-
Bitterroot Bio, a Series A biotech focusing on cardio-immunology, is seeking an?Associate Director, Legal?to join my team and tackle exciting challenges to advance our mission. This is a unique opportunity to shape our journey as we move into Phase 2 and prepare for our next financing round. If you’re driven, curious, and ready to make an impact, we’d love to hear from you! Update: The link to the position has changed -- please click here: https://lnkd.in/gkWrKxmc
-
Bitterroot Bio is excited to announce results of its phase 1 first-in-human trial of BRB-002 in healthy volunteers. Phase 1 demonstration of BRB-002’s excellent safety and high potency is an important milestone as we advance this first-in-class, immune modulating biologic inhibitor of CD47 toward treatment of atherosclerotic cardiovascular disease. Detailed data from the Phase 1 study of BRB-002 will be presented at the American College of Cardiology Annual Scientific Session in March, 2025. Read the full Press Release here: https://bit.ly/3WyzSzB #BitterrootBio?#BRB002 #cardiovascular #drugdevelopment
-
-
Thank you for the?dedication?of?our?talented Team and?Partners. We look forward to a joyful season and a 2025 filled with heart, and transformative progress for cardiovascular patients everywhere. Cheers! #Bitterrootforward?
-
-
Bitterroot Bio is excited to join academic, industry, regulatory, and cardiovascular patient representatives at the CVCT Forum this week in Washington, D.C.! #CVCTForum #BitterrootBio
-
-
Bitterroot Bio will be at Evercore’s HealthCONx Conference on Dec. 3rd in Coral Gables. We are looking forward to connecting with industry leaders to help drive the future of cardiovascular care forward. #HealthCONx #HealthcareInnovation
-